Esophageal Cancer - Pipeline Review, H1 2015


#246230

270pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, Esophageal Cancer Pipeline Review, H1 2015, provides an overview of the Esophageal Cancers therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Esophageal Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Esophageal Cancer and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Esophageal Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Esophageal Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Esophageal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Esophageal Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Esophageal Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Esophageal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents 2
List of Tables 5
List of Figures 7

Introduction 8
Global Markets Direct Report Coverage 8
Esophageal Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Esophageal Cancer - Overview 10
Pipeline Products for Esophageal Cancer - Comparative Analysis 11
Esophageal Cancer - Therapeutics under Development by Companies 12
Esophageal Cancer - Therapeutics under Investigation by Universities/Institutes 17
Esophageal Cancer - Pipeline Products Glance 18
Late Stage Products 18
Clinical Stage Products 19
Early Stage Products 20
Esophageal Cancer - Products under Development by Companies 21
Esophageal Cancer - Products under Investigation by Universities/Institutes 25
Esophageal Cancer - Companies Involved in Therapeutics Development 26
Advantagene, Inc. 26
Advaxis, Inc. 27
Amgen Inc. 28
ArQule, Inc. 29
Aslan Pharmaceuticals Pte. Ltd. 30
AstraZeneca PLC 31
AVEO Pharmaceuticals, Inc. 32
Bellicum Pharmaceuticals, Inc. 33
Boehringer Ingelheim GmbH 34
Bristol-Myers Squibb Company 35
Celgene Corporation 36
Cellectar Biosciences, Inc. 37
Cerulean Pharma, Inc. 38
Daiichi Sankyo Company, Limited 39
Genmab A/S 40
GlaxoSmithKline plc 41
Glycotope GmbH 42
Hutchison MediPharma Limited 43
ImmunoFrontier, Inc. 44
ImmunoGen, Inc. 45
Immunomedics, Inc. 46
Karyopharm Therapeutics, Inc. 47
Mebiopharm Co., Ltd. 48
Meiji Seika Pharma Co., Ltd. 49
Merrimack Pharmaceuticals, Inc. 50
Novartis AG 51
Omeros Corporation 52
Omnitura Therapeutics Inc. 53
Oncolys BioPharma Inc. 54
Ono Pharmaceutical Co., Ltd. 55
Patrys Limited 56
Pfizer Inc. 57
Precision Biologics, Inc. 58
Proteo, Inc. 59
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 60
Supratek Pharma Inc. 61
Synta Pharmaceuticals Corp. 62
Takara Bio Inc. 63
Transgene Biotek Limited 64
Zhejiang BetaPharma Co., Ltd. 65
Esophageal Cancer - Therapeutics Assessment 66
Assessment by Monotherapy Products 66
Assessment by Target 67
Assessment by Mechanism of Action 70
Assessment by Route of Administration 73
Assessment by Molecule Type 75
Drug Profiles 77
1-BB1 - Drug Profile 77
ADXS-HER2 - Drug Profile 79
afatinib - Drug Profile 80
alpelisib - Drug Profile 84
AMG-337 - Drug Profile 86
binimetinib - Drug Profile 87
BMS-833923 - Drug Profile 91
BPX-601 - Drug Profile 93
Cell Therapy 1 for Oncology - Drug Profile 94
Cell Therapy to Target NY-ESO-1 for Oncology - Drug Profile 95
cetuximab biobetter - Drug Profile 96
CRLX-101 - Drug Profile 97
dacomitinib - Drug Profile 99
DKN-01 - Drug Profile 101
doxorubicin - Drug Profile 103
Elafin - Drug Profile 105
ficlatuzumab - Drug Profile 108
ganetespib - Drug Profile 111
gefitinib - Drug Profile 115
Gene Therapy for Esophageal Cancer - Drug Profile 120
Gene Therapy to Activate p53 for Oncology - Drug Profile 121
GSK-2256098 - Drug Profile 122
HMPL-309 - Drug Profile 124
HMPL-813 - Drug Profile 125
HuMax-TF-ADC - Drug Profile 126
I131-CLR1404 - Drug Profile 127
icotinib hydrochloride - Drug Profile 129
IMF-001 - Drug Profile 130
IMGN-289 - Drug Profile 131
IMMU-132 - Drug Profile 132
LJM-716 - Drug Profile 133
MBP-426 - Drug Profile 135
MM-111 - Drug Profile 137
MMD-37K - Drug Profile 139
MVX-ONCO-1 - Drug Profile 140
NEO-201 - Drug Profile 141
nimotuzumab - Drug Profile 142
nivolumab (recombinant) - Drug Profile 145
OBP-301 - Drug Profile 150
OMN-54 - Drug Profile 152
paclitaxel albumin bound - Drug Profile 154
panitumumab - Drug Profile 158
PAT-LM1 - Drug Profile 161
patritumab - Drug Profile 162
rAAV-VICN003 - Drug Profile 164
rhLT28-171 - Drug Profile 165
selinexor - Drug Profile 166
Small Molecule to Antagonize GPR39 for Esophageal Squamous Cell Carcinoma and Obesity-Related Type-2 Diabetes - Drug Profile 170
Small Molecule to Target LGR5 for Esophageal Adenocarcinoma - Drug Profile 171
Small Molecules to Inhibit Histone Demethylase for Esophageal Cancer - Drug Profile 172
talaporfin sodium - Drug Profile 173
TBI-1201 - Drug Profile 176
TBL-0805E - Drug Profile 178
tivantinib - Drug Profile 179
Vaccine for Esophageal Cancer - Drug Profile 182
Vaccine for Oncology - Drug Profile 183
varlitinib - Drug Profile 184
Esophageal Cancer - Recent Pipeline Updates 186
Esophageal Cancer - Dormant Projects 253
Esophageal Cancer - Discontinued Products 256
Esophageal Cancer - Product Development Milestones 257
Featured News & Press Releases 257

Appendix 265
Methodology 265
Coverage 265
Secondary Research 265
Primary Research 265
Expert Panel Validation 265
Contact Us 265
Disclaimer 266

Number of Products under Development for Esophageal Cancer, H1 2015 14
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 17
Number of Products under Development by Companies, H1 2015 (Contd..1) 18
Number of Products under Development by Companies, H1 2015 (Contd..2) 19
Number of Products under Development by Companies, H1 2015 (Contd..3) 20
Number of Products under Investigation by Universities/Institutes, H1 2015 21
Comparative Analysis by Late Stage Development, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 23
Comparative Analysis by Early Stage Development, H1 2015 24
Products under Development by Companies, H1 2015 25
Products under Development by Companies, H1 2015 (Contd..1) 26
Products under Development by Companies, H1 2015 (Contd..2) 27
Products under Development by Companies, H1 2015 (Contd..3) 28
Products under Investigation by Universities/Institutes, H1 2015 29
Esophageal Cancer - Pipeline by Advantagene, Inc., H1 2015 30
Esophageal Cancer - Pipeline by Advaxis, Inc., H1 2015 31
Esophageal Cancer - Pipeline by Amgen Inc., H1 2015 32
Esophageal Cancer - Pipeline by ArQule, Inc., H1 2015 33
Esophageal Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 34
Esophageal Cancer - Pipeline by AstraZeneca PLC, H1 2015 35
Esophageal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 36
Esophageal Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 37
Esophageal Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 38
Esophageal Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 39
Esophageal Cancer - Pipeline by Celgene Corporation, H1 2015 40
Esophageal Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2015 41
Esophageal Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 42
Esophageal Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 43
Esophageal Cancer - Pipeline by Genmab A/S, H1 2015 44
Esophageal Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 45
Esophageal Cancer - Pipeline by Glycotope GmbH, H1 2015 46
Esophageal Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015 47
Esophageal Cancer - Pipeline by ImmunoFrontier, Inc., H1 2015 48
Esophageal Cancer - Pipeline by ImmunoGen, Inc., H1 2015 49
Esophageal Cancer - Pipeline by Immunomedics, Inc., H1 2015 50
Esophageal Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 51
Esophageal Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2015 52
Esophageal Cancer - Pipeline by Meiji Seika Pharma Co., Ltd., H1 2015 53
Esophageal Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 54
Esophageal Cancer - Pipeline by Novartis AG, H1 2015 55
Esophageal Cancer - Pipeline by Omeros Corporation, H1 2015 56
Esophageal Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2015 57
Esophageal Cancer - Pipeline by Oncolys BioPharma Inc., H1 2015 58
Esophageal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 59
Esophageal Cancer - Pipeline by Patrys Limited, H1 2015 60
Esophageal Cancer - Pipeline by Pfizer Inc., H1 2015 61
Esophageal Cancer - Pipeline by Precision Biologics, Inc., H1 2015 62
Esophageal Cancer - Pipeline by Proteo, Inc., H1 2015 63
Esophageal Cancer - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H1 2015 64
Esophageal Cancer - Pipeline by Supratek Pharma Inc., H1 2015 65
Esophageal Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 66
Esophageal Cancer - Pipeline by Takara Bio Inc., H1 2015 67
Esophageal Cancer - Pipeline by Transgene Biotek Limited, H1 2015 68
Esophageal Cancer - Pipeline by Zhejiang BetaPharma Co., Ltd., H1 2015 69
Assessment by Monotherapy Products, H1 2015 70
Number of Products by Stage and Target, H1 2015 72
Number of Products by Stage and Mechanism of Action, H1 2015 75
Number of Products by Stage and Route of Administration, H1 2015 78
Number of Products by Stage and Molecule Type, H1 2015 80
Esophageal Cancer Therapeutics - Recent Pipeline Updates, H1 2015 190
Esophageal Cancer - Dormant Projects, H1 2015 257
Esophageal Cancer - Dormant Projects (Contd..1), H1 2015 258
Esophageal Cancer - Dormant Projects (Contd..2), H1 2015 259
Esophageal Cancer - Discontinued Products, H1 2015 260

Number of Products under Development for Esophageal Cancer, H1 2015 14
Number of Products under Development for Esophageal Cancer - Comparative Analysis, H1 2015 15
Number of Products under Development by Companies, H1 2015 16
Number of Products under Investigation by Universities/Institutes, H1 2015 21
Comparative Analysis by Late Stage Development, H1 2015 22
Comparative Analysis by Clinical Stage Development, H1 2015 23
Comparative Analysis by Early Stage Products, H1 2015 24
Assessment by Monotherapy Products, H1 2015 70
Number of Products by Top 10 Targets, H1 2015 71
Number of Products by Stage and Top 10 Targets, H1 2015 71
Number of Products by Top 10 Mechanism of Actions, H1 2015 74
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 74
Number of Products by Top 10 Routes of Administration, H1 2015 77
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 77
Number of Products by Top 10 Molecule Types, H1 2015 79
Number of Products by Stage and Top 10 Molecule Types, H1 2015 79